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ABSTRACT
Objective: A systematic review and meta-analysis to
investigate the impact of electronic nicotine delivery
systems (ENDS) and/or electronic non-nicotine delivery
systems (ENNDS) versus no smoking cessation aid, or
alternative smoking cessation aids, in cigarette
smokers on long-term tobacco use.
Data sources: Searches of MEDLINE, EMBASE,
PsycInfo, CINAHL, CENTRAL and Web of Science up to
December 2015.
Study selection: Randomised controlled trials (RCTs)
and prospective cohort studies.
Data extraction: Three pairs of reviewers
independently screened potentially eligible articles,
extracted data from included studies on populations,
interventions and outcomes and assessed their risk of
bias. We used the Grading of Recommendations
Assessment, Development and Evaluation approach to
rate overall certainty of the evidence by outcome.
Data synthesis: Three randomised trials including
1007 participants and nine cohorts including 13 115
participants proved eligible. Results provided by only
two RCTs suggest a possible increase in tobacco
smoking cessation with ENDS in comparison with
ENNDS (RR 2.03, 95% CI 0.94 to 4.38; p=0.07;
I2=0%, risk difference (RD) 64/1000 over 6 to
12 months, low-certainty evidence). Results from
cohort studies suggested a possible reduction in quit
rates with use of ENDS compared with no use of ENDS
(OR 0.74, 95% CI 0.55 to 1.00; p=0.051; I2=56%, very
low certainty).
Conclusions: There is very limited evidence regarding
the impact of ENDS or ENNDS on tobacco smoking
cessation, reduction or adverse effects: data from RCTs
are of low certainty and observational studies of very
low certainty. The limitations of the cohort studies led
us to a rating of very low-certainty evidence from
which no credible inferences can be drawn. Lack of
usefulness with regard to address the question of
e-cigarettes’ efficacy on smoking reduction and
cessation was largely due to poor reporting. This
review underlines the need to conduct well-designed
trials measuring biochemically validated outcomes and
adverse effects.
INTRODUCTION
Tobacco smokers who quit their habit reduce
their risk of developing and dying from
tobacco-related diseases.1–4 Psychosocial5–7
and pharmacological interventions (eg, nico-
tine replacement therapy (NRT))5–7 increase
the likelihood of quitting cigarettes. Even
with these aids, however, most smokers fail to
quit.
Strengths and limitations of this study
▪ Strengths of our review include a comprehensive
search; assessment of eligibility, risk of bias and
data abstraction independently and in duplicate;
assessment of risk of bias that included a sensi-
tivity analysis addressing loss to follow-up; and
use of the Grading of Recommendations
Assessment, Development and Evaluation
approach in rating the certainty of evidence for
each outcome.
▪ The primary limitation of our review is the low
certainty consequent on study limitations.
Moreover, loss to follow-up was substantial, and
our sensitivity analysis demonstrated the vulner-
ability of borderline effects to missing data. The
limitations of the cohort studies led us to a
rating of very low-certainty evidence from which
no credible inferences can be drawn.
▪ The small number of studies made it impossible
to address our subgroup hypotheses related
dose–response of nicotine, more versus less fre-
quent use of e-cigarettes or the relative impact of
newer versus older e-cigarette models.
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Electronic nicotine delivery systems (ENDS) and elec-
tronic non-nicotine delivery systems (ENNDS) represent
a potential third option for those seeking to stop
smoking. ENDS are devices that deliver nicotine in an
aerosolised form, while ENNDS devices are labelled as
not containing nicotine (though labelling may not
always be accurate). In theory, these devices as well as
the nicotine inhalers may facilitate quitting smoking to a
greater degree than other nicotine-based products or no
intervention because they deal, at least partly, with the
behavioural and sensory aspects of smoking addiction
(eg, hand mouth movement).8 The debate about the
role of ENDS in smoking cessation, however, is com-
pounded by the lack of clear evidence about their value
as a smoking cessation tool, their potential to hook
tobacco-naïve youth on nicotine as well as act as a bridge
to combustible tobacco use.9 While evidence about all
these aspects of ENDS is accumulating, establishing
their real place in smoking cessation is essential to
outline the public health context of considering them as
potential harm-reduced products. There are, however,
other reasons for ENDS use such as for relaxation or
recreation (ie, the same reason people smoke), with the
possibility that adverse health effects may be less than
conventional smoking.
There are many types of ENDS. The cigalikes are the
ﬁrst generation of ENDS that provide an appearance of
tobacco cigarettes; they are not rechargeable. The
second generation of ENDS looks like a pen, allows the
user to mix ﬂavours and may contain a preﬁlled or a
reﬁllable cartridge. The third generation of ENDS
includes variable wattage devices and are used only with
reﬁllable tank systems. The fourth generation contains a
large, reﬁllable cartridge and has a tank-style design.
A previous Cochrane systematic review8 summarised
results from randomised controlled trials (RCTs) and
cohort studies. The authors included two RCTs and 11
cohort studies, and concluded that there was evidence
to support the potential beneﬁt of ENDS in increasing
tobacco smoking cessation.8 The certainty of evidence
supporting this conclusion was, however, deemed low,
primarily due to the small number of trials resulting in
wide CIs around effect estimates.8 Another systematic
review10 including a total of six studies (RCTs, cohort
and cross-sectional studies) involving 7551 participants
concluded that ENDS is associated with smoking cessa-
tion and reduction; however, the included studies were
heterogeneous, due to different study designs and
gender variation. One other review11 comparing e-
cigarettes with other nicotine replacement therapies or
placebo included ﬁve studies (RCTs and controlled
before–after studies) and concluded that participants
using nicotine e-cigarettes were more likely to stop
smoking, but noted no statistically signiﬁcant differ-
ences.11 In a more recent systematic review, Kalkhoran
and Glantz9 included 20 studies (15 cohort studies, 3
cross-sectional studies and 2 clinical trials), and found
28% lower odds rates of quitting cigarettes in those who
used e-cigarettes compared with those who did not use
e-cigarettes; however, the methodological aspects of the
observational studies were rated as unclear or high on
outcome assessors, and a RCT was rated as high risk of
performance and attrition bias.
Previous reviews were, however, limited in that they did
not include all studies in this rapidly evolving ﬁeld, and
all but one did not use the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach to rating quality of evidence. We therefore con-
ducted an updated systematic review of RCTs and cohort
studies that assessed the impact of ENDS and/or ENNDS
versus no smoking cessation aid or alternative smoking
cessation aids on long-term tobacco use, among cigarette
smokers, regardless of whether the users were using them
as part of a quit attempt.
METHODS
We adhered to methods described in the Cochrane
Handbook for Intervention Reviews.12 Our reporting
adheres to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA)13 and meta-analysis
of observational studies in epidemiology (MOOSE) state-
ments.14 This work was commissioned by the WHO.
Eligibility criteria
▸ Study designs: RCTs and prospective cohort studies.
▸ Participants: cigarette smokers, regardless of whether
the users were using them as part of a quit attempt.
▸ Interventions: ENDS or ENNDS.
▸ Comparators:
– no smoking cessation aid;
– alternative non-electronic smoking cessation aid,
including NRT, behavioural and/or pharmaco-
logical cessation aids (eg, bupropion and vareni-
cline) and
– alternative electronic smoking cessation aid (ENDS
or ENNDS).
▸ Outcomes:
– tobacco smoking cessation, with preference to bio-
chemically validated outcomes (eg, carbon monox-
ide (CO)) measured at 6 months or longer
follow-up;
– reduction in cigarette use of at least 50% and
– serious (eg, pneumonia, myocardial infarction) and
non-serious (eg, nausea, vomiting) adverse events
measured at 1 week or longer follow-up.
Data source and searches
A previous Cochrane review with similar eligibility cri-
teria ran a comprehensive search strategy up to July
2014.8 Using medical subject headings (MeSH) based
on the terms ‘electronic nicotine,’ ‘smoking-cessation,’
‘tobacco-use-disorder,’ ‘tobacco-smoking’ and ‘quit’, we
replicated the search strategy of that review8 in Medline,
EMBASE, PsycInfo, CINAHL, Cochrane Central Register
of Controlled Trials (CENTRAL), ISI Web of Science
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and the trial registry (clinicaltrials.gov). The appendix
table 1 shows the search strategy for Ovid MEDLINE.
This strategy was adapted for the other databases and
run from 1 April 2014 to 29 December 2015. We did not
impose any language restrictions.
In addition, we established a literature surveillance
strategy based on the weekly search alerts by Centers for
Disease Control and prevention (CDC)’s Smoking and
Health Resource Library of published articles (http://
nccd.cdc.gov/shrl/NewCitationsSearch.aspx) as well as
the Gene Borio’s daily news items (http://www.tobacco.
org). The surveillance strategy started from the time of
running the comprehensive literature search up to the
time of the submission of this manuscript.
Selection of studies
Three pairs of reviewers underwent calibration exercises
and used standardised pilot tested screening forms. They
worked in teams of two and independently screened all
titles and abstracts identiﬁed by the literature search,
obtained full-text articles of all potentially eligible studies
and evaluated them for eligibility. Reviewers resolved dis-
agreement by discussion or, if necessary, with third party
adjudication. We also considered studies reported only as
conference abstracts. For each study, we cite all articles
that used data from that study.
Data extraction
Reviewers underwent calibration exercises, and worked
in pairs to independently extract data from included
studies. They resolved disagreement by discussion or, if
necessary, with third party adjudication. They abstracted
the following data using a pretested data extraction
form: study design; participants; interventions; compara-
tors; outcome assessed and relevant statistical data.
When available, we prioritised CO measurements as evi-
dence of quitting. When CO measurement was unavail-
able, we used self-report measures of quitting.
Risk of bias assessment
Reviewers, working in pairs, independently assessed the
risk of bias of included RCTs using a modiﬁed version of
the Cochrane Collaboration’s instrument15 (http:/distil-
lercer.com/resources/).16 That version includes nine
domains: adequacy of sequence generation, allocation
sequence concealment, blinding of participants and
caregivers, blinding of data collectors, blinding for
outcome assessment, blinding of data analysts, incom-
plete outcome data, selective outcome reporting and the
presence of other potential sources of bias not
accounted for in the previously cited domains.16
For cohort studies, reviewers independently assessed
risk of bias with a modiﬁed version of the Ottawa–
Newcastle instrument17 that includes conﬁdence in
assessment of exposure and outcome, adjusted analysis
for differences between groups in prognostic character-
istics and missing data.17 For incomplete outcome data in
individual studies (RCTs and prospective cohort studies),
we stipulated as low risk of bias for loss to follow-up of
<10% and a difference of <5% in missing data between
intervention/exposure and control groups.
When information regarding risk of bias or other aspects
of methods or results was unavailable, we attempted to
contact study authors for additional information.
Certainty of evidence
We summarised the evidence and assessed its certainty
separately for bodies of evidence from RCTs and cohort
studies. We used the GRADE methodology to rate cer-
tainty of the evidence for each outcome as high, moder-
ate, low or very low.18 In the GRADE approach, RCTs
begin as high certainty and cohort studies as low cer-
tainty. Detailed GRADE guidance was used to assess
overall risk of bias,19 imprecision,20 inconsistency,21
indirectness22 and publication bias23 and to summarise
results in an evidence proﬁle. We planned to assess pub-
lication bias through visual inspection of funnel plots for
each outcome in which we identiﬁed 10 or more eligible
studies; however, we were not able to because there were
an insufﬁcient number of studies to allow for this assess-
ment. Cohort studies can be rated up for a large effect
size, evidence of dose–response gradient or if all plaus-
ible confounding would reduce an apparent effect.24
Data synthesis and statistical analysis
We analysed all outcomes as dichotomous variables. In
three-arm studies, we combined results from arms
judged to be sufﬁciently similar (eg, Caponnetto 2013,25
two arms with similar ENDS regimens: 7.2 mg ENDS
and 7.2 mg ENDS plus 5.4 mg ENDS). When studies
reported results for daily or intensive use of ENDS separ-
ately from non-daily or less intensive use, we included
only the daily/intensive use in the primary pooled ana-
lysis (eg, Brose 2015,26–28 we excluded patients with non-
daily users; and Biener and Hargraves,29 we excluded
patients with intermittent deﬁned use). We conducted a
sensitivity analysis in which we included all ENDS users,
daily/intensive and intermittent/less intensive use. For
this analysis, when necessary, we assumed a correlation
of 0.5 between the effects in the daily/intensive and
intermittent/less intensive groups.
We synthesised the evidence separately for bodies of
evidence from RCTs and cohort studies. For RCTs, we
calculated pooled Mantel-Haenszel risk ratios (RRs) and
associated 95% CIs using random effects models. For
observational studies, we pooled adjusted ORs using
random effects models.
After calculating pooled relative effects, we also calcu-
lated absolute effects and 95% CI. For each outcome, we
multiplied the pooled RR and its 95% CI by the median
probability of that outcome. We obtained the median prob-
ability from the control groups of the available randomised
trials. We planned to perform separate analyses for com-
parisons with interventions consisting of ENDS and/or
ENNDS and each type of control interventions with known
different effects (no smoking cessation aid; alternative
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Table 1 Study characteristics related to design of study, setting, number of participants, mean age, gender, inclusion and exclusion criteria, and follow-up.
Author, year
Design of
study Location
No.*
participants Mean age
No. male
(%) Inclusion criteria Exclusion criteria
Follow-up
(months)
Randomized controlled trials
Adriaens,
201430
Parallel
RCT
Leuven, Belgium 50 ENDS1: 44.7
ENDS2: 46.0
ENDS and e-liquid**: 40.3
21 (43.7) Being a smoker for at least three years;
smoking a minimum of 10 factory-made
cigarettes per day and not having the intention
to quit smoking in the near future, but willing to
try out a less unhealthy alternative
Self-reported diabetes; severe
allergies; asthma or other
respiratory diseases; psychiatric
problems; dependence on
chemicals other than nicotine,
pregnancy; breast feeding; high
blood pressure; cardiovascular
disease; currently using any kind of
smoking cessation therapy and prior
use of an e-cigarette
8
Bullen,
201331–36
Parallel
RCT
New Zealand 657 16 mg ENDS: 43.6
21 mg patches NRT: 40.4
ENNDS: 43.2
252 (38.3) Aged 18 years or older; had smoked ten or
more cigarettes per day for the past year;
wanted to stop smoking; and could provide
consent
Pregnant and breastfeeding women;
people using cessation drugs or in
an existing cessation programme;
those reporting heart attack, stroke,
or severe angina in the previous
two weeks; and those with poorly
controlled medical disorders,
allergies, or other chemical
dependence
6
Caponnetto,
201325
Parallel
RCT
Catania, Italy 300 7.2 mg ENDS: 45.9
7.2 mg ENDS+5.4 mg
ENDS: 43.9
ENNDS: 42.2
190 (63.3) Smoke 10 factory made cigarettes per day
(cig/day) for at least the past five years; age
18–70 years; in good general health; not
currently attempting to quit smoking or wishing
to do so in the next 30 days; committed to
follow the trial procedures
Symptomatic cardiovascular
disease; symptomatic respiratory
disease; regular psychotropic
medication use; current or past
history of alcohol abuse; use of
smokeless tobacco or nicotine
replacement therapy, and
pregnancy or breastfeeding
12
Cohort studies
Al-Delaimy,
201537
Cohort California, US 628 Not reported 478 (47.8) Residents of California; aged 18 to 59 years
who had smoked at least 100 cigarettes during
their lifetime and are current smokers
Participants who reported that they
“might use e-cig” or changed their
reporting at follow-up, as they did
not represent a definitive group of
users or never-users e-cig and
might overlap with both
12
Biener, 201538 Cohort Dallas and
Indianapolis
areas, US
1374 Not reported 383 (55.2) Adults smokers residing in the Dallas and
Indianapolis metropolitan areas, who had been
interviewed by telephone and gave permission
to be re-contacted
Anyone over 65 years old 36
Brose,
201540–42
Cohort Web-based,
United Kingdom
3891*** ENDS
Among daily users: 45.7
Among non-daily users: 45.2
No ENDSα: 45.7
2,015
(49.6)
Members were invited by e-mail to participate
in an online study about smoking and who
answered a screening question about their
past-year smoking status
Baseline pipe or cigar smokers, and
follow-up pipe or cigar smokers or
unsure about smoking status
12
Hajek 201546 Cohort Europe 100 ENDS: 41.8
No ENDS: 39
57 (57) All smokers joining the UK Stop Smoking
Services in addition to the standard treatment
(weekly support and stop smoking medications
including NRT and varenicline).
No exclusion criteria 4 weeksβ
Continued
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Table 1 Continued
Author, year
Design of
study Location
No.*
participants Mean age
No. male
(%) Inclusion criteria Exclusion criteria
Follow-up
(months)
Harrington
201546
Cohort US 979 46.0**** 525 (53.6) Hospitalized cigarette smokers at a tertiary
care medical center; self-identified smoker who
smoked at least one puff in previous 30 days;
English speaking and reading; over age 18
and; cognitively and physically able to
participate in study
Pregnant 6
Manzoli,
201543
Cohort Abruzzo and
Lazio region, Italy
1355 ENDS only:
45.2
Tobacco cigarettes only:
44.2
Dual smoking: 44.3
757 (55.9) Aged between 30 and 75 years; smoker of
e-cig (inhaling at least 50 puffs per week)
containing nicotine since six or more months
(E-cig only group); smoker of at least one
traditional cigarette per day since six or more
months (traditional cigarettes only group);
smoker of both electronic and traditional
cigarettes (at least one per day) since six or
more months (mixed Group)
Illicit drug use, breastfeeding or
pregnancy, major depression or
other psychiatric conditions, severe
allergies, active antihypertensive
medication, angina pectoris, past
episodes of major cardiovascular
diseases (myocardial infarction,
stroke/TIA, congestive heart failure,
COPD, cancer of the lung,
esophagus, larynx, oral cavity,
bladder, pancreas, kidney, stomach,
cervix, and myeloid leukemia
12
Borderud,
201439
Cohort New York, US 1074 ENDS use+ behavioral and
pharmacological treatment:
56.3
No ENDS+behavioral and
pharmacological treatment:
55.6
467 (43.5) Patients with cancer referred to a tobacco
cessation program who provided data on their
recent (past 30 days) e-cig use
No exclusion criteria 6 to 12
Prochaska
201444
Cohort US 956 39.0**** 478
(50.0)
Adult daily smokers (at least 5 cigarettes/day
with serious mental illness at four psychiatric
hospitals in the San Francisco Bay Area
Non-English speaking; medical
contraindications to NRT use
(pregnancy, recent myocardial
infarction); and lack of capacity to
consent as determined by a 3-item
screener of study purpose, risks,
and benefits
18
Vickerman
201345
Cohort US 2,758€ Used ENDS one month or
more: 48.1
Used ENDS less than one
month: 45.3
No ENDS: 49.6
913 (36.9) Participants from six state quitlines who
registered for tobacco cessation services.
Adult tobacco users, consented to evaluation
follow-up, spoke English, provided a valid
phone number, and completed at least one
intervention call
No exclusion criteria 7
no.: number; e-cig: e-cigarettes; ENDS: Electronic nicotine delivery system; ENNDS: electronic non-nicotine delivery systems; RCT: randomized controlled trial; US: United States; ENDS1 and
ENDS2: the e-cig groups received the e-cig and four bottles of e-liquid at session 1 (group e-cig1 received the “Joyetech eGo-C” and group e-cig2 received the “Kanger T2-CC”); at session 2,
participants’ empty bottles were replenished up to again four bottles and at session 3, they were allowed to keep the remaining bottles.
*Randomized or at baseline
**For the first two months control group consisted of no e-cigarettes use. After that period, the participants of control group received the e-cig and e-liquid. ENDS1=“Joyetech eGo-C” e-cig and
ENDS2=“Kanger T2-CC” e-cig.
***The 4117 were reported in a publication that focused on baseline characteristics, not on the use of e-cigarettes and changes in smoking behavior, so the remaining 53 participants are
irrelevant to this review.
****Mean age of the overall population.
αThe comparator comprises of current non-users of e-cig, which included never-users and those who had previously tried but were not using at the moment.
βHajek 2015 was the only study that entered in the review due to meet the criteria for adverse events.
€But only 2,476 asnwered the question “Have you ever used e-cigarettes, electronic, or vapor cigarettes?”
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non-electronic smoking cessation aid including NRT and
alternative electronic smoking cessation aid (ENDS or
ENNDS)). For meta-analyses, we used 6 months data or
the nearest follow-up to 6 months available.
For dealing with missing data, we used complete case
as our primary analysis; that is, we excluded participants
with missing data. If results of the primary analysis
achieved or approached statistical signiﬁcance, we con-
ducted sensitivity analyses to test the robustness of those
results. Speciﬁcally, we conducted a plausible worst-case
sensitivity analysis in which all participants with missing
data from the arm of the study with the lower quit rates
were assumed to have three times the quit rate as those
with complete data, and those with missing data from
the other arm were assumed to have the same quit rate
as participants with complete data.30 31
We assessed variability in results across studies by using
the I2 statistic and the p-value for the χ2 test of hetero-
geneity provided by Review Manager. We used Review
Manager (RevMan) (V.5.3; Nordic Cochrane Centre,
Cochrane) for all analyses.32
RESULTS
Study selection
Figure 1 presents the process of identifying eligible
studies, including publications in the last systematic
review,8 citations identiﬁed through search in elec-
tronic databases and studies identiﬁed through contact
with experts in the ﬁeld. Based on title and abstract
screening, we assessed 69 full texts of which we
included 19 publications describing three RCTs involv-
ing 1007 participants25 33–39 and nine cohort studies
with a total of 13 115 participants.26–29 40–46 The inter-
observer agreement for the full-text screening was sub-
stantial (kappa 0.73).
We contacted the authors of the 12 included studies, 9
of whom26–29 33 41 43 44 46 supplied us with all requested
data; authors of further 3 studies25 42 46 did not supply
the requested information (see online supplementary
appendix table S2).
Study characteristics
Table 1 describes study characteristics related to design
of study, setting, number of participants, mean age,
gender, inclusion and exclusion criteria and follow-up.
Five studies25–28 33 42 46 were conducted largely in
Europe, six in the USA,29 40 41 43–45 and one in New
Zealand.34–39 Randomised trials sample size ranged from
5033 to 657,34–39 and observational studies from 10046 to
3891.26–28 Typical participants were women in their 40 s
and 50 s. Studies followed participants from 4 weeks46 to
36 months.29
Figure 1 PRISMA diagram of included studies. *McRobbie, 2014.8 **Further two publications from one RCT included by the
Cochrane review were identified only in our search strategy. ***Further one publication from one cohort study identified by our
search strategy was identified throughout the expert search.
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Table 2 Study characteristics related to population, intervention or exposure groups, comparator, and assessed outcomes.
Author, year Population
No.* of participants
intend to quit
smoking
No.* of participants in
intervention or exposure
groups and comparator
Description of
intervention or
exposure groups
Description of
comparators Measured outcomes
Definition of quitters or
abstinence
Randomized controlled trials
Adriaens,
201433
Participants unwilling to quit
smoking (participants from the
control group kept on smoking
regular tobacco cigarettes
during the first eight weeks of
the study)
Yes 0
No 50
ENDS 1: 16
ENDS 2: 17
Control/ENDS: 17
ENDS (“Joyetech
eGo-C”)
ENDS
E-cigarettes (“Kanger
T2-CC”)
ENDS and
e-liquid**
Quitting, defined as eCO of
5 ppm or smaller;
questionnaire self-report of
reduction in cigarettes
of>50% or complete quitting
No more cigarette
smoking
Bullen,
201334–39
Had smoked ten or more
cigarettes per day for the past
year, interested in quitting
Yes 657
No 0
ENDS: 289
NRT: 295
ENNDS: 73
16 mg nicotine ENDS 21 mg patches
NRT
ENNDS
Continuous smoking
abstinence, biochemically
verified (eCO measurement
<10 ppm); seven day point
prevalence abstinence;
reduction; and adverse
events
Abstinence allowing ≤5
cigarettes in total, and
proportion reporting no
smoking of tobacco
cigarettes, not a puff, in
the past 7 days
Caponnetto,
201325
Smokers not intending to quit Yes 0
No 300
ENDS 1: 100
ENDS 2: 100
ENNDS: 100
7.2 mg nicotine ENDS
7.2 mg nicotine ENDS
+5.4 mg nicotine ENDS
ENNDS Self-report of reduction in
cigarettes of>50%;
abstinence from smoking,
defined as complete
self-reported abstinence
from tobacco smoking - not
even a puff, biochemically
verified (eCO measurement
≤7 ppm); and adverse
events
Complete self-reported
abstinence from tobacco
smoking - not even a
puff
Cohort studies
Al-Delaimy,
201540
Current smokers; regardless of
whether the users were using
ENDS as part of a quit attempt
Yes 415
No 542
ENDS: 236Ψ
No ENDS: 392Ψ
ENDS No ENDS Quit attempts; 20% reduction
in monthly no. of cigarettes;
and current abstinence from
cigarette use
Duration of abstinence of
one month or longer to
be currently abstinent
Biener,
201529
All respondents had reported
being cigarette smokers at
baseline; regardless of whether
the users were using ENDS as
part of a quit attempt
Yes 364β
No 331€
1374$ ENDS£ intermittent use
ENDS£ intensive use
No ENDS (used
once or twice
ENDS)
Smoking cessation; and
reduction in motivation to
quit smoking among those
who had not quit, not
otherwise specified
Smoking cessation was
defined as abstinence
from cigarettes for at
least one month
Brose,
201526–28
Current smokers; regardless of
whether the users were using
ENDS as part of a quit attempt
Not reported ENDS: 1507
No ENDS: 2610
ENDS daily
ENDS non-daily
No ENDS€ Quit attemptsϕ; cessationϖ;
and substantial reduction
defined as a reduction by at
least 50% from baseline
CPD to follow-up CPD
Change from being a
smoker at baseline to
being an ex-smoker at
follow-up was coded as
cessation
Hajek, 201546 69% (n=69) accepted e-cigs as
part of their smoking cessation
treatment
Not reported ENDS: 69
No ENDS: 31
ENDS was offered to all
smokers in addition to
the standard treatment
(weekly support and stop
smoking medications
including NRT and
varenicline)
No ENDS Self-reported abstinence
was biochemically validated
by exhaled CO levels in
end-expired breath using a
cut-off point on 9ppm,
adverse events
Self-reported abstinence
from cigarettes at 4
weeks
ENDS No ENDS
Continued
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Table 2 Continued
Author, year Population
No.* of participants
intend to quit
smoking
No.* of participants in
intervention or exposure
groups and comparator
Description of
intervention or
exposure groups
Description of
comparators Measured outcomes
Definition of quitters or
abstinence
Harrington,
201545
Hospitalized cigarette smokers.
All were cigarette smokers
initially; regardless of whether
the users were using ENDS as
part of a quit attempt
Yes: 220***
No: not reported
ENDS: 171
No ENDS: 759
Quitting smoking based on
30-day point prevalence at 6
months
Only self-reported
quitting smoking
Manzoli,
201542
Smokers of ≥1 tobacco
cigarette/day (tobacco smokers),
users of any type of e-cig,
inhaling ≥50 puffs weekly
(e-smokers), or smokers of both
tobacco and e-cig (dual
smokers)
Not reported ENDS: 343
Tobacco and ENDS: 319
Tobacco only: 693
ENDS
Tobacco and ENDS
Tobacco
cigarettes only
Abstinence, proportion of
quitters, biochemically
verified (eCO
measurement>7ppm),
reduce tobacco smoking,
and serious adverse events
Percentage of subjects
reporting sustained (30
days) smoking
abstinence from tobacco
smoking
Borderud,
201441
Patients who presented for
cancer treatment and identified
as current smokers (any
tobacco use within the past 30
days); regardless of whether the
users were using ENDS as part
of a quit attempt
Yes 633¥
No 42¥
ENDS: 285
No ENDS: 789
ENDS£+Evidence-based
behavioral and
pharmacologic treatment
No ENDS
+Evidence-based
behavioral and
pharmacologic
treatment
Smoking cessation by
self-report
Patients were asked if
they had smoked even a
puff of a (traditional)
cigarette within the last 7
days
Prochaska,
201443
Adult daily smokers with serious
mental illness; regardless of
whether the users were using
ENDS as part of a quit attempt
At baseline, 24%
intended to quit
smoking in the next
month
ENDS: 101
No ENDS: 855
ENDS No ENDS Smoking cessation by
self-report and,
biochemically verified (CO
and cotinine)
Past 7 day tobacco
abstinence
Vickerman,
201344
Adult tobacco current or past
users; regardless of whether the
users were using ENDS as part
of a quit attempt
Not reported ENDS: 765
No ENDS: 1,711
ENDS used for 1 month
or more
ENDS used for less than
1 month
No ENDS (never
tried)
Tobacco abstinence Self-reported 30-day
tobacco abstinence at 7
month follow-up
no.: number; C: comparator group; CPD: cigarettes smoked per day; e-cig: e-cigarettes; ENDS: Electronic nicotine delivery system; ENNDS: electronic non-nicotine delivery systems; eCO:
exhaled breath carbon monoxide; NE: non-exposure group; NRT: Nicotine replacement therapy.
*Numbers randomized or at baseline.
**For the first two months control group consisted of no e-cigarettes use. After that period, the participants of control group received the e-cig and e-liquid. ENDS1=“Joyetech eGo-C” e-cig and
ENDS2=“Kanger T2-CC” e-cig.
***Only among those who reported any previous use of e-cigs.
αInformation retrieved through contact with author.
€The comparator comprises of current non-users of e-cig, which included never-users and those who had previously tried but were not using at the moment.
ΨParticipants who will never use e-cig plus those who never heard of e-cig=392; participants who have used e-cig=236 (numbers taken from the California Smokers Cohort, a longitudinal survey).
βIntentions to quit smoking, those who tried e-cigarettes only once or twice are grouped with never users (“non-users/triers”).
€Intermittent use (i.e., used regularly, but not daily for more than 1 month) plus intensive use (i.e., used e-cig daily for at least 1 month).
$No. of the whole sample including comparator.
£All ENDS.
¥The other participants either quit more than a month ago but less than six months, less than a month ago, or more than six months ago.
ϕSmokers and recent ex-smokers were asked about the number of attempts to stop they had made in the previous year. Those reporting at least one attempt and 37 respondents who did not
report an attempt but had stopped smoking be- tween baseline and follow-up were coded as having made an attempt.
ϖChange from being a smoker at baseline to being an ex-smoker at follow-up was coded as cessation.
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Table 3 Mean number of conventional cigarettes used per day at baseline and the end of study*
Author, year Groups
Mean no. of conventional
cigarettes used per day at
baseline
Mean no. of conventional
cigarettes used per day at
the end of study
Biochemically quitters
(no. of events per no. of
total participants)
Self-reported quitters
(no. of events per no. of
total participants)
Adriaens, 201433 ENDS 1 20.1 7.0† 3/13 4/13
ENDS 2 20.6 8.1† 3/12 3/12
Control/ENDS‡,§ 16.7 7.7† 4/13 4/13
Bullen, 201334–39 ENDS 18.4 0.7¶ 21/241 Not available
ENNDS 17.7 0.7 3/57 Not available
NRT 17.6 0.8¶ 17/215 Not available
Caponnetto,
201325
7.2 mg ENDS 19.0 (14.0–25.0)** 12 (5.8–20)**,†† Combined ENDS groups: 22/128 Not available
7.2 mg ENDS
plus 5.4 mg
ENDS
21.0 (15.0–26.0)** 14 (6–20)**,†† Not available
ENNDS 22.0 (15.0–27.0)** 12 (9–20)**,†† 4/55 Not available
Al-Delaimy,
201540
ENDS 14.1‡‡ 13.8§§ Not available 12/179
ENNDS Not available 32/145
Biener, 201529 ENDS
intermittent use
16.7¶¶ Not available Not available Combined ENDS groups: 42/
331
ENDS intensive
use
17.1¶¶ Not available Not available
No ENDS 15.4¶¶ Not available Not available 82/364
Brose, 201526–28 ENDS daily users 14.3 13.0*** Not available 7/86
ENDS non-daily
users
13.5 13.9*** Not available 25/263
No ENDS††† 13.3 13.5 Not available 168/1307
Hajek, 201546 ENDS Not available Not available Not applicable‡‡‡ Not applicable‡‡‡
No ENDS Not available Not available Not applicable‡‡‡ Not applicable‡‡‡
Harrington,
201545
ENDS 14.1§§§ 10.3§§§ Not available 21/171
No ENDS 11.9§§§ 9.8§§§ Not available 62/464
Manzoli, 201542 ENDS only Not available 12 Not available Not available
Tobacco
cigarettes only
14.1 12.8 101/491 Not available
Dual smoking 14.9 9.3 51/232 Not available
Borderud, 201441 ENDS 13.7 12.3 Not available 25/58
No ENDS 12.4 10.1 Not available 158/356
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Table 3 Continued
Author, year Groups
Mean no. of conventional
cigarettes used per day at
baseline
Mean no. of conventional
cigarettes used per day at
the end of study
Biochemically quitters
(no. of events per no. of
total participants)
Self-reported quitters
(no. of events per no. of
total participants)
Prochaska,
201443
ENDS 17.0 10.0 21/101 Not available
No ENDS 17.0 10.1 162/855 Not available
Vickerman,
201344
ENDS used for
1 month or more
19.4 13.5 Not available 59/273
ENDS used for
less than 1 month
18.9 14.0 Not available 73/439
No ENDS (never
tried)
18.1 12.9 Not available 535/1711
*When authors provided data for different time points, we presented the data for the longest follow-up.
†8 months from start of intervention.
‡Control group consisted of received the e-cig and e-liquid (six bottles) for 2 months at the end of session 3 (eight of the 16 participants of the control group received the ‘Joyetech eGo-C’ and
the remaining eight participants received the ‘Kanger T2-CC’).
§For the first 2 months control group consisted of no e-cigarettes use. After that period, the participants of control group received the e-cig and e-liquid. ENDS1=’Joyetech eGo-C’ e-cig and
ENDS2=’Kanger T2-CC’ e-cig.
¶For those reporting smoking at least one cigarette in past 7 days.
**Data shown as median and interquartile.
††At 6 months after the last laboratory session.
‡‡Of the 1000 subjects, 993 responded to the question “How many conventional cigarettes smoked per day during the past 30 days”.
§§Of the 1000 subjects, 881 responded to the question “How many cigarettes smoked per day during the past 30 days.”
¶¶Number of conventional cigarettes used in the prior month at baseline.
***No. of cigarette per week divided by 7 days.
†††The comparator comprises of current non-users of e-cig which included never-users and those who had previously tried but were not using at the moment.
‡‡‡Not applicable because they followed participants only for 4 weeks, but the study reported adverse events at 1 week or longer.
§§§Data for baseline current e-cig users.
e-cig, eletronic cigarettes; ENDS, electronic nicotine delivery system; ENDS1 and ENDS 2, the e-cig groups received the e-cig and four bottles of e-liquid at session 1 (group e-cig1 received the
‘Joyetech eGo-C’ and group e-cig2 received the ‘Kanger T2-CC’); at session 2; ENNDS, electronic non-nicotine delivery systems; No., number; RYO, roll your own (loose tobacco) cigarettes.
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Table 4 Risk of bias assessment for the randomised controlled trials
Author, year
Was the
randomisation
sequence
adequately
generated?
Was
allocation
adequately
concealed?
Was there
blinding of
participants?
Was there
blinding of
caregivers?
Was there
blinding of
data
collectors?
Was there
blinding of
statistician?
Was there
blinding of
outcome
assessors?
Was loss to
follow-up
(missing
outcome data)
infrequent?*
Are reports of
the study free of
suggestion of
selective
outcome
reporting?
Was the study
apparently free
of other
problems that
could put it at a
risk of bias?
Randomised controlled trials assessing ENDS vs ENNDS
Bullen,
201334–39
Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely no Definitely yes Definitely yes
Caponnetto,
201325
Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely yes Definitely no Definitely yes Definitely yes
Randomised controlled trials assessing ENDS vs other quitting mechanisms
Adriaens,
201433
Definitely yes Probably no Probably no Probably no Probably no Probably no Probably no Definitely no Probably yes Probably yes
Bullen,
201334–39
Definitely yes Definitely yes Definitely no Definitely no Probably yes Probably yes Definitely yes Definitely no Definitely yes Definitely yes
All answers as: definitely yes (low risk of bias), probably yes, probably no, definitely no (high risk of bias).
*Defined as less than 10% loss to outcome data or difference between groups less than 5% and those excluded are not likely to have made a material difference in the effect observed.
ENDS, electronic nicotine delivery systems; ENNDS, electronic non-nicotine delivery systems.
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Table 2 describes study characteristics related to popu-
lation, intervention or exposure groups, comparator and
assessed outcomes.
Of the three RCTs, one compared ENDS with NRT
and ENNDS,34–39 another compared different concen-
trations of ENDS with ENNDS25 and the third compared
different types of ENDS.33 Only the Borderud study41
included participants who were also currently receiving
other behavioural and pharmacologic treatment. The
participants from Vickerman 201344 study were all
enrolled in a state quitline programme that provided
behavioural treatment and in some cases NRT. All nine
cohort studies26–29 34–46 compared ENDS with no use of
ENDS26–29 40 41 or tobacco cigarettes only;42 in one,41
exposure and non-exposure groups received behavioural
and other pharmacologic treatment.
Table 3 describes the mean number of conventional
cigarettes used per day at baseline and the end of study.
The mean number at baseline ranged from 11.9 in
the no ENDS group45 to 20.6 in the ENDS group.33 In
only two studies26–28 45 the mean number of conven-
tional cigarettes used per day presented a reduction
from the baseline to the end of study in the ENDS
group compared with the no ENDS groups, mainly in
the daily users.26–28 No included study addressed users
of combustible tobacco products other than cigarettes.
Online supplementary appendix table S3 presents the
types of e-cigarettes used in the included studies. The
three RCTs25 33 36–39 evaluated only ENDS-type cigalikes.
A total of 23.7% of the participants from Brose 201526–28
study used tank and in the Hajek 201546 study partici-
pants used either cigalike or tank. The remaining
studies did not report the type of ENDS used.
Risk of bias
Figures 2 and 3, and table 4, describe the risk of bias
assessment for the RCTs.
The major issue regarding risk of bias in the RCTs of
ENDS versus ENNDS was the extent of missing outcome
data.25 34–39 RCTs comparing ENDS with other nicotine
replacement therapies had additional problems of con-
cealment of randomisation33 and blinding.33–39
Figure 4 and table 5 describe the risk of bias assess-
ment of the cohort studies.
Seven26–29 40–42 44 45 of nine cohort studies were rated
as high risk of bias for limitations in matching exposed
and unexposed groups or adjusting analysis for progno-
sis variables; conﬁdence in the assessment of the pres-
ence or absence of prognostic factors; conﬁdence in the
assessment of outcome and similarity of cointerventions
between groups; all studies suffered from high risk of
bias for missing outcome data.
Outcomes
The mean number of conventional cigarettes/tobacco
products used per day at the end of the studies ranged
from 0.734–39 in ENDS and ENNDS groups to 13.926–28
among non-daily users of ENDS (table 3). The three
RCTs25 33–39 and one cohort study42 biochemically con-
ﬁrmed nicotine abstinence while the others presented
only self-reported data26–29 40 41 43–45 (table 3).
Tobacco cessation smoking
Synthesised results from RCTs
Results from two RCTs25 34–39 suggest a possible increase
in smoking cessation with ENDS in comparison with
Figure 4 Risk of bias for cohort studies.
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Table 5 Risk of bias assessment of the cohort studies
Author,
year
Was selection of
exposed and
non-exposed
cohorts drawn
from the same
population?*
Can we be
confident in
the
assessment of
exposure?†
Can we be
confident that
the outcome
of interest
was not
present at
start of
study?‡
Did the study
match exposed and
unexposed for all
variables that are
associated with the
outcome of interest
or did the statistical
analysis adjust for
these prognostic
variables?§
Can we be
confident in the
assessment of
the presence or
absence of
prognostic
factors?¶
Can we be
confident in
the
assessment of
outcome?**
Was the
follow-up of
cohorts
adequate?††
Were
cointerventions
similar between
groups?‡‡
Al-Delaimy
201540
Definitely yes Probably yes Definitely yes Definitely no Definitely no Definitely no Definitely no Probably no
Biener
201529
Definitely yes Probably yes Definitely yes Definitely no Definitely no Definitely no Definitely no Probably no
Brose
201526–28
Definitely yes Probably yes Probably no Definitely no Definitely no Definitely no Definitely no Probably no
Hajek
201546
Probably yes Probably yes Probably yes Definitely no Probably yes Probably yes Probably yes Probably no
Harrington
201545
Definitely yes Definitely no Definitely no Definitely no Definitely no Definitely no Definitely no Definitely no
Manzoli
201542
Definitely yes Probably yes Definitely no Definitely no Definitely no Probably no Definitely no Probably no
Borderud
201441
Definitely yes Probably yes Definitely yes Definitely no Definitely no Definitely no Definitely no Definitely yes
Prochaska
201443
Definitely yes Probably yes Definitely yes Definitely yes Probably yes Definitely no Definitely yes Probably No
Vickerman
201344
Probably yes Definitely no Definitely no Definitely no Definitely no Definitely no Definitely no Definitely no
All answers as: definitely yes (low risk of bias), probably yes, probably no, definitely no (high risk of bias).
*Examples of low risk of bias: Exposed and unexposed drawn from same administrative data base of patients presenting at same points of care over the same time frame.
†This means that investigators accurately assess the use of ENDS at baseline.
‡This means that smoking cessation was not present at the start of the study.
§Examples of low risk of bias: comprehensive matching or adjustment for all plausible prognostic variables.
¶Examples of low risk of bias: Interview of all participants; self-completed survey from all participants; review of charts with reproducibility demonstrated; from data base with documentation of
accuracy of abstraction of prognostic data.
**Outcome self-reported was considered as definitely no for adequate assessment. Smoking abstinence, biochemically verified was considered as definitely yes for adequate assessment.
††Defined as less than 10% loss to outcome data or subjects lost to follow-up unlikely to introduce bias.
‡‡Examples of low risk of bias: Most or all relevant cointerventions that might influence the outcome of interest are documented to be similar in the exposed and unexposed.
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ENNDS (RR 2.03, 95% CI 0.94 to 4.38; p=0.07; I2=0%,
risk difference (RD) 64/1000 over 6 to 12 months, low-
quality evidence) (ﬁgure 5, table 6).
A plausible worse case sensitivity analysis yielded
results that were inconsistent with the primary complete
case analysis and fail to show a difference in the effects
of ENDS in comparison with ENNDS (RR 1.16, 95% CI
0.72 to 1.87; p=0.54; I2=0%) (see online supplementary
appendix ﬁgure 1). Certainty in evidence was rated
down to low because of imprecision and risk of bias, due
to missing outcome data in all studies and lack of blind-
ing of participants,34–39 caregivers, data collectors, statis-
tician and outcome assessors in the ENDS versus other
NRT studies (ﬁgure 2, tables 4 and 6).
Adriaens 201433 also compared two types of ENDS
and ENDS and e-liquid; results failed to show a differ-
ence between the ENDS groups with a very wide CI (RR
1.15, 95% CI 0.28 to 4.76, p=0.84).
Bullen 201334–39 also compared ENDS and ENNDS
with NRT; results failed to show a difference between
these groups with a very wide CI (RR 1.10, 95% CI 0.60
to 2.03, p=0.76) and (RR 0.67, 95% CI 0.20 to 2.19,
p=0.50), respectively.
Synthesised results from cohort studies
The adjusted OR from primary meta-analysis of eight
cohort studies26–29 40–45 comparing ENDS with no ENDS
without reported concomitant interventions failed to
show a beneﬁt in cessation smoking (OR 0.74, 95% CI
0.55 to 1.00; p=0.051; I2=56%) (ﬁgure 6). A sensitivity
analysis from the eight cohort studies26–29 40–45 using
any rather than daily use of ENDS for Brose study,26–28
intensive (used e-cigarettes daily for at least 1 month)
and intermittent use (used regularly, but not daily for
more than 1 month) of ENDS for Biener study29 and
any use versus never used for Vickerman study44 sug-
gested a reduction in cessation smoking rates with ENDS
(adjusted OR 0.69, 95% CI 0.53 to 0.91; p=0.01; I2=59%)
(see online supplementary appendix ﬁgure 2).
Another sensitivity analysis from the same eight cohort
studies26–29 40–45 examined whether low and high risk of
bias limited to the one characteristic in which the
studies differed substantially: conﬁdence in whether the
outcome was present at the beginning of the study.
Although there were substantial differences in the point
estimates in the low risk of bias group (adjusted OR
1.00, 95% CI 0.51 to 1.94; p=1.00; I2=67%) and the high
risk of bias group (adjusted OR 0.62, 95% CI 0.50 to
0.77; p<0.001; I2=0%), the difference is easily explained
by chance (interaction p-value was 0.19) (see online
supplementary appendix ﬁgure 3).
A second sensitivity analysis from the same eight
cohort studies26–29 40–45 examined whether low and high
risk of bias limited to ‘two or fewer domains rated as
low risk of bias’ versus ‘three or more domains rated as
low risk of bias’ differed substantially. There were sub-
stantial differences in the point estimates between the
‘two or fewer domains rated as low risk of bias’ group
(adjusted OR 0.61, 95% CI 0.49 to 0.75; p<0.001;
I2=0%) and the ‘three or more domains rated as low
risk of bias’ (adjusted OR 1.26, 95% CI 0.68 to 2.33;
p=0.46; I2=51%), with an interaction p-value of 0.03 (see
online supplementary appendix ﬁgure 4).
Certainty in evidence from the observational studies
was rated down from low to very low because of risk of
bias due to missing outcome data, imprecision in the
assessment of prognostic factors and outcomes (ﬁgure 4,
tables 5 and 7), as well as inconsistency in the results.
Borderud 201441 reported cessation smoking in 25 out
of 58 patients with cancer using ENDS plus behavioural
and pharmacologic treatment versus in 158 out of 356
patients with cancer who received only behavioural and
pharmacologic treatment (adjusted OR 0.97, 95% CI
0.71 to 1.33).
Reduction in cigarette use of at least 50%
Synthesised results from RCTs
Two RCTs25 34–39 results failed to show a difference
between ENDS-type cigalikes versus ENNDS group with
regards to reduction in cigarettes but with a very wide CI
(RR 0.97, 95% CI 0.57 to 1.66; p=0.92; I2=61%) (see
online supplementary appendix ﬁgure 5). Certainties in
evidence were rated low because of imprecision and risk
of bias25 34–36 38 39 (ﬁgure 2, tables 4 and 6).
Synthesised results from cohort studies
Two studies26–29 suggested increased reduction rates in
those with greater versus lesser use of ENDS. Biener29
reported an adjusted OR for quitting of 6.07 (95% CI
1.11 to 33.2) in those with intensive use versus an OR of
0.31 (0.04, 2.80) in those with intermittent use. Brose26–28
reported a greater likelihood of substantial reduction
(but not quitting) in those with daily use of ENDS (OR
Figure 5 Meta-analysis of RCTs on cessation smoking comparing ENDS versus ENND.
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2.49, 95% CI 1.14 to 5.45) but not those with intermittent
use (OR 0.85 0.43 to 1.71).
Adverse effects
Synthesised results from RCTs
The Bullen 201334–37 39 study reported serious side
effects in 27 out of 241 participants in the 16 mg ENDS
group and 5 out of 57 for the ENNDS group followed at
6 months; results failed to show a difference between
these groups with a very wide CI (OR 1.31, 95% CI 0.48
to 3.57; p=0.59). Results suggested possible increase in
side effects in the 21 mg nicotine patches group (14 of
215) in comparison with ENDS (OR 1.81, 95% CI 0.92 to
3.55; p=0.08). Serious side effects include death (n=1, in
nicotine e-cigarettes group), life threatening illness (n=1,
in nicotine e-cigarettes group), admission to hospital or
prolongation of hospital stay (12% of all events in nico-
tine e-cigarettes group, 8% in patches group and 11% in
placebo e-cigarettes group), persistent or signiﬁcant dis-
ability or incapacity and other medically important events
(6% of all events in nicotine e-cigarettes group, 4% in
patches group and 3% placebo e-cigarettes group).
Adriaens 201433 study reported no serious adverse
events in ENDS groups as well as in the e-liquid group at
8 months of follow-up; however at 1 week from start of
intervention there were three cases of non-serious
adverse events in the ENDS groups.
Caponnetto 201325 mentioned that no serious adverse
events occurred during the study and authors found a
signiﬁcant reduction in frequency of reported symptoms
compared with baseline.
Synthesised results from cohort studies
Manzoli42 reported no signiﬁcant differences in self-
reported serious side effects, but observed four cases of
pneumonia, four COPD exacerbations, three myocardial
infarctions and one angina as possibly related serious
side effects: two among the ENDS users (both switched
to tobacco smoking during follow-up); six among
tobacco smokers (three quit all smoking) and four
among tobacco and ENDS smokers.
Hajek 201546 reported one leak irritating a partici-
pant’s mouth and some reports of irritation at the back
of the throat and minor coughing. The remaining
studies did not report adverse effects.
DISCUSSION
Main findings
Based on pooled data from two randomised trials with
481 participants, we found evidence for a possible
increase in tobacco smoking cessation with ENDS in
comparison with ENNDS (ﬁgure 5). The evidence is,
however, of low certainty: the 95% CI of the relative risk
crossed 1.0 and a plausible worse case sensitivity analysis
to assess the risks of bias associated with missing partici-
pant data yielded results that were inconsistent with the
primary complete case analysis (see online
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supplementary appendix ﬁgure 1). Furthermore, in all
these RCTs, the ENDS tested were of earlier generation;
it is unknown whether providing later generation of e-
cigarettes or a realistic scenario of allowing users to
choose e-cigarettes based on self-preference would have
greater beneﬁt. There was no robust evidence of side
effects associated with ENDS in the RCTs.
Cohort studies provide very low-certainty evidence sug-
gesting a possible reduction in quit rates with use of
ENDS compared with no use of ENDS (ﬁgure 6). These
studies had a number of limitations: an unknown
number of these participants were not using ENDS as a
cessation device; some were not using ENDS during a
quit attempt; many did not have immediate plans to quit
smoking and some may have already failed attempts to
stop smoking. In our risk of bias assessment, we judged
that seven of nine studies did not have optimal adjust-
ment for prognostic variables. Further, as any cohort
study, the results are vulnerable to residual confounding.
In particular, use of ENDS may reﬂect the degree of
commitment to smoking cessation, and it may be the
degree of commitment, rather than use of ENDS, that is
responsible for the change in quit rates. For instance,
the ﬁnding in two studies that daily use of ENDS, but
not intermittent use, increased quit/reduction rates
could be interpreted as evidence of the effectiveness of
daily use. An alternative interpretation, however, is that
those that used ENDS daily were more motivated to stop
smoking, and the increased motivation, rather than daily
use of ENDS, was responsible for their degree of
success. It is worth to mention that motivation to quit
smoking is a major determinant of success regardless of
the aid used.
In terms of bias against ENDS, cohort studies some-
times enrol smokers already using ENDS and still
smoking. Such individuals may already be failing in their
attempts to stop smoking. If so, enrolling these partici-
pants will underestimate ENDS beneﬁcial effects.
Additional concerns with cohort studies include their
failure to provide optimal adjustment for prognostic vari-
ables or provide data regarding use of alternative
smoking reduction aids.
Strengths and limitations
Strengths of our review include a comprehensive search;
assessment of eligibility, risk of bias and data abstraction
independently and in duplicate; assessment of risk of
bias that included a sensitivity analysis addressing loss to
follow-up and use of the GRADE approach in rating the
certainty of evidence for each outcome.
The primary limitation of our review is the low cer-
tainty consequent on study limitations. We identiﬁed
only a small number of RCTs with a modest number of
participants resulting wide CIs. Moreover, loss to
follow-up was substantial, and our sensitivity analysis
demonstrated the vulnerability of borderline effects to
missing data. The limitations of the cohort studies led us
to a rating of very low-certainty evidence from which no
credible inferences can be drawn.
Another limitation of this review is the fact that we
could not address our hypothesis about increased rates
in smoking cessation in those who used e-cigarettes with
higher concentrations of nicotine compared with those
using less nicotine, or daily e-cigarette users compared
with non-daily e-cigarette users, or those who use newer
forms of ENDS compared with users of ﬁrst generation
devices due to lack of evidence. However, although
these assumptions seems logical, nicotine delivery from
ENDS depends on other factors such as the efﬁciency of
the device in aerosolising the liquid and user experi-
ence, apart from the concentration of nicotine in the
ENDS liquid.
Furthermore, whether or not ENDS are an effective
aid in the cessation of smoking may depend on whether
the users were using ENDS as part of a quit attempt or
not, and this may play an important role also as a
possible confounder. Data is not yet available to conduct
a subgroup analysis addressing this hypothesis.
Figure 6 Meta-analysis of
cohort studies on cessation
smoking with adjusted ORs.
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Subsequent trials should help provide information
regarding whether their impact on cessation of smoking
depends on whether users were intended to quit
smoking, as well as the other unresolved issues.
Other limitations of this review were the fact of having
insufﬁcient number of included studies to allow the
complete statistical analysis that we had planned. We
were not able to assess publication bias because there
were <10 eligible studies addressing the same outcome
in a meta-analysis. We also planned to perform subgroup
analyses according to the characteristics of:
▸ participants (commitment to stopping smoking, use
of e-cigarettes at baseline);
▸ interventions (dose of nicotine delivered by the e-
cigarette, frequency of use of the e-cigarette and type
of e-cigarettes) and
▸ concomitant interventions in e-cigarettes and control
groups.
However, we also were not able to conduct these ana-
lyses because they did not meet our minimal criteria,
which were at least ﬁve studies available, with at least two
in each subgroup. A ﬁnal statistical limitation is that we
calculated differences from 6 to 12 months of follow-up.
Absolute differences may differ across this time frame
and constitute a source of variability. Moreover, there
are three schools of thought with respect to use of ﬁxed
and random effect models: those who prefer always to
use ﬁxed effects, those who prefer (almost) always
random effects and those who would choose ﬁxed and
random depending on the degree of heterogeneity.
Each argument has its proponents within the statistical
community. The argument in favour of the second
rather than the third is 1) there is always some hetero-
geneity, so any threshold of switching models is arbitrary
and 2) when there is little heterogeneity, ﬁxed and
random yield similar or identical results, so one might as
well commit oneself to random from the start. We ﬁnd
these two arguments compelling; thus, our choice.
Finally, another limitation of the observational studies
in this review is the potential for selection bias as the
populations compared differ in terms of intention to
quit. Furthermore, in all these RCTs, the ENDS tested
were earlier generation; it is possible that later gener-
ation of e-cigarettes would have greater beneﬁt.
Although this review presents several limitations, the
issue is whether one should dismiss these results entirely
or consider them bearing in mind the limitations. The
latter represent our view of the matter.
Relation to prior work
The previous Cochrane review8 concluded that due to
low event rates and wide CIs, only low-certainty evidence
was available from studies comparing ENDS with
ENNDS. We excluded some studies included in that
Cochrane review as they were either case series, cross-
sectional or did not include one arm with ENDS/
ENNDS compared with alternative strategies. We also
included one additional RCT,33 and nine new cohort
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studies,26–29 40–44 46 not included in the Cochrane
review. The rationale for including the prospective
cohort studies in our review was that it was anticipated
that the search would return few RCTs. The authors of
the Cochrane review found that ENDS is a useful aid to
stop smoking long term compared with ENNDS.
Another review10 including two of our three
RCTs,25 34–39 and further two case series and two cross-
sectional studies, assessed the impact of e-cigarettes in
achieving smoking abstinence or reduction in cigarette
consumption among current smokers who had used the
devices for 6 months or more. The authors concluded
that e-cigarette use is associated with smoking cessation;
these results are similar to our meta-analysis comparing
ENDS with ENNDS (ﬁgure 5). Khoudigian’s 2016
review11 reported a non-statistically signiﬁcant trend
toward smoking cessation in adults using nicotine e-
cigarettes compared with other therapies or placebo.
However, the review by Kalkhoran and Glatz 20169 con-
cluded that e-cigarettes are associated with signiﬁcantly
less quitting among smokers.
Implications
Existing smoking reduction aids such as NRT are effect-
ive, but their impact is limited: the proportion of those
who quit when using these aids remains small. The avail-
able evidence, of low or very low quality, can neither
verify nor exclude the hypothesis that, because they
address nicotine addiction and potentially deal with
behavioural and sensory aspects of cigarette use, ENDS
may be more effective than other nicotine replacement
strategies. This is an important ﬁnding, and raises ques-
tions regarding how effective it may be addressing the
behavioural and sensory aspects of cigarette use in their
addictive potential. Thus, the focus of subsequent work
should perhaps be on the dose and delivery of nicotine,
though teasing out the nicotine effects from sensory
aspects is likely to be challenging. It is possible that type
of ENDS or dose of exposure may inﬂuence quit rates,
and that newer models may be more effective, but there
is insufﬁcient data to provide insight into these issues.
Lack of usefulness with regard to address the question of
e- cigarettes’ efﬁcacy on smoking reduction and cessa-
tion was largely due to poor reporting.
Therefore, owing to the limitations of the studies
included in this analysis it is impossible to make strong
inferences regarding whether e-cigarette use promotes,
has no effect or hinders smoking cessation. This review
underlines the need to conduct well-designed trials in
this ﬁeld measuring biochemically validated outcomes
and adverse effects.
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